tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Biohaven price target lowered to $49 from $50 at BofA

BofA lowered the firm’s price target on Biohaven (BHVN) to $49 from $50 and keeps a Buy rating on the shares. The Q2 update “offered some minor pipeline updates,” including an announcement that the Phase 3 troriluzole study in OCD failed, leading to discontinuation, the analyst tells investors. After updating its model for Q2 financials, the firm removed troriluzole in OCD from its model and fine-tuned operating expense estimates to align with expected cash burn, the analyst noted.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1